| 发明名称 | Stable liquid formulations of dimer VEGF antagonists | ||
| 摘要 | Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | ||
| 申请公布号 | US9416167(B2) | 申请公布日期 | 2016.08.16 |
| 申请号 | US201414550385 | 申请日期 | 2014.11.21 |
| 申请人 | Regeneron Pharmaceuticals, Inc. | 发明人 | Dix Daniel;Frye Kelly;Kautz Susan |
| 分类号 | A61K38/17;A61K38/18;A61K39/00;A61K47/02;A61K31/4172;A61K38/16;A61K9/08;A61K47/26;C07K14/71;A61K9/00;A61K9/19;A61K31/7012;A61K47/10;A61K47/18;A61K47/22 | 主分类号 | A61K38/17 |
| 代理机构 | Kutak Rock LLP | 代理人 | Kutak Rock LLP ;Zahner Joseph E. |
| 主权项 | 1. A stable pharmaceutical formulation comprising: (a) 50-100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist fusion protein dimer consisting of two identical fusion polypeptides consisting essentially of (i) the immunoglobulin-like domain 2 of the human Flt1 VEGF receptor, (ii) the immunoglobulin-like domain 3 of the human Flk1 or the human Flt4 VEGF receptor, and (iii) an immunoglobulin Fc domain; (b) 5-50 mM histidine; (c) 0.1-3.0% polyethylene glycol (PEG) 3350; (d) 0.24-3.0% glycine; and (e) 0.5-6.0% sucrose, pH 6.3-6.5. | ||
| 地址 | Tarrytown NY US | ||